Extensive disease among potential candidates for hemi-ablative focal therapy for prostate cancer

Toshikazu Takeda, Amy L. Tin, Renato B. Corradi, Ricardo Alvim, Takeshi Hashimoto, Yujiro Ito, Daniel P. Nguyen, Maha Mamoor, Nicola L. Robertson, Hebert A. Vargas, Nicole E. Benfante, Daniel D. Sjoberg, James A. Eastham, Peter T. Scardino, Samson W. Fine, Mototsugu Oya, Karim A. Touijer

Research output: Contribution to journalArticle

Abstract

Objective: To examine a set of proposed eligibility factors for hemi-ablative focal therapy in prostate cancer and to determine the likelihood of residual extensive disease. Methods: We retrospectively analyzed data from 98 patients with unilateral prostate cancer on biopsy with detailed tumor maps from whole-mount slides and preoperative magnetic resonance imaging data. These patients met the focal therapy consensus meeting inclusion criteria (prostate-specific antigen <15 ng/mL, clinical stage T1c-T2a and Gleason score 3 + 3 or 3 + 4 on needle biopsy), and underwent radical prostatectomy between 2000 and 2014. Extensive disease was defined as having Gleason pattern 4/5 in bilateral lobes, any extraprostatic extension, seminal vesicle invasion or lymph node invasion. Both lobes of the prostate were scored on magnetic resonance imaging. Preoperative characteristics including biopsy and magnetic resonance imaging data were used to predict extensive disease. Results: Among our cohort of 98 patients, 40% (95% CI 30–50%) had extensive disease. A total of 33% (95% CI 24–43%) had Gleason pattern 4/5 in both lobes with a median Gleason pattern 4/5 tumor volume in the biopsy negative lobe of 0.06 cm3, 17 patients had pathological tumor stage ≥3 and one patient had lymph node invasion. Conclusions: An important number of patients meeting the focal therapy consensus meeting inclusion criteria can present extensive disease. Further studies using targeted biopsies might provide more accurate information about the selection of focal therapy candidates.

Original languageEnglish
JournalInternational Journal of Urology
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Prostatic Neoplasms
Biopsy
Magnetic Resonance Imaging
Therapeutics
Lymph Nodes
Neoplasm Grading
Seminal Vesicles
Needle Biopsy
Prostate-Specific Antigen
Prostatectomy
Tumor Burden
Prostate
Neoplasms

Keywords

  • ablation techniques
  • biopsy
  • magnetic resonance imaging
  • pathology
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Extensive disease among potential candidates for hemi-ablative focal therapy for prostate cancer. / Takeda, Toshikazu; Tin, Amy L.; Corradi, Renato B.; Alvim, Ricardo; Hashimoto, Takeshi; Ito, Yujiro; Nguyen, Daniel P.; Mamoor, Maha; Robertson, Nicola L.; Vargas, Hebert A.; Benfante, Nicole E.; Sjoberg, Daniel D.; Eastham, James A.; Scardino, Peter T.; Fine, Samson W.; Oya, Mototsugu; Touijer, Karim A.

In: International Journal of Urology, 01.01.2019.

Research output: Contribution to journalArticle

Takeda, T, Tin, AL, Corradi, RB, Alvim, R, Hashimoto, T, Ito, Y, Nguyen, DP, Mamoor, M, Robertson, NL, Vargas, HA, Benfante, NE, Sjoberg, DD, Eastham, JA, Scardino, PT, Fine, SW, Oya, M & Touijer, KA 2019, 'Extensive disease among potential candidates for hemi-ablative focal therapy for prostate cancer', International Journal of Urology. https://doi.org/10.1111/iju.14161
Takeda, Toshikazu ; Tin, Amy L. ; Corradi, Renato B. ; Alvim, Ricardo ; Hashimoto, Takeshi ; Ito, Yujiro ; Nguyen, Daniel P. ; Mamoor, Maha ; Robertson, Nicola L. ; Vargas, Hebert A. ; Benfante, Nicole E. ; Sjoberg, Daniel D. ; Eastham, James A. ; Scardino, Peter T. ; Fine, Samson W. ; Oya, Mototsugu ; Touijer, Karim A. / Extensive disease among potential candidates for hemi-ablative focal therapy for prostate cancer. In: International Journal of Urology. 2019.
@article{a0549e49886f498ba1b077d4ee5bfd8f,
title = "Extensive disease among potential candidates for hemi-ablative focal therapy for prostate cancer",
abstract = "Objective: To examine a set of proposed eligibility factors for hemi-ablative focal therapy in prostate cancer and to determine the likelihood of residual extensive disease. Methods: We retrospectively analyzed data from 98 patients with unilateral prostate cancer on biopsy with detailed tumor maps from whole-mount slides and preoperative magnetic resonance imaging data. These patients met the focal therapy consensus meeting inclusion criteria (prostate-specific antigen <15 ng/mL, clinical stage T1c-T2a and Gleason score 3 + 3 or 3 + 4 on needle biopsy), and underwent radical prostatectomy between 2000 and 2014. Extensive disease was defined as having Gleason pattern 4/5 in bilateral lobes, any extraprostatic extension, seminal vesicle invasion or lymph node invasion. Both lobes of the prostate were scored on magnetic resonance imaging. Preoperative characteristics including biopsy and magnetic resonance imaging data were used to predict extensive disease. Results: Among our cohort of 98 patients, 40{\%} (95{\%} CI 30–50{\%}) had extensive disease. A total of 33{\%} (95{\%} CI 24–43{\%}) had Gleason pattern 4/5 in both lobes with a median Gleason pattern 4/5 tumor volume in the biopsy negative lobe of 0.06 cm3, 17 patients had pathological tumor stage ≥3 and one patient had lymph node invasion. Conclusions: An important number of patients meeting the focal therapy consensus meeting inclusion criteria can present extensive disease. Further studies using targeted biopsies might provide more accurate information about the selection of focal therapy candidates.",
keywords = "ablation techniques, biopsy, magnetic resonance imaging, pathology, prostatic neoplasms",
author = "Toshikazu Takeda and Tin, {Amy L.} and Corradi, {Renato B.} and Ricardo Alvim and Takeshi Hashimoto and Yujiro Ito and Nguyen, {Daniel P.} and Maha Mamoor and Robertson, {Nicola L.} and Vargas, {Hebert A.} and Benfante, {Nicole E.} and Sjoberg, {Daniel D.} and Eastham, {James A.} and Scardino, {Peter T.} and Fine, {Samson W.} and Mototsugu Oya and Touijer, {Karim A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/iju.14161",
language = "English",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Extensive disease among potential candidates for hemi-ablative focal therapy for prostate cancer

AU - Takeda, Toshikazu

AU - Tin, Amy L.

AU - Corradi, Renato B.

AU - Alvim, Ricardo

AU - Hashimoto, Takeshi

AU - Ito, Yujiro

AU - Nguyen, Daniel P.

AU - Mamoor, Maha

AU - Robertson, Nicola L.

AU - Vargas, Hebert A.

AU - Benfante, Nicole E.

AU - Sjoberg, Daniel D.

AU - Eastham, James A.

AU - Scardino, Peter T.

AU - Fine, Samson W.

AU - Oya, Mototsugu

AU - Touijer, Karim A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To examine a set of proposed eligibility factors for hemi-ablative focal therapy in prostate cancer and to determine the likelihood of residual extensive disease. Methods: We retrospectively analyzed data from 98 patients with unilateral prostate cancer on biopsy with detailed tumor maps from whole-mount slides and preoperative magnetic resonance imaging data. These patients met the focal therapy consensus meeting inclusion criteria (prostate-specific antigen <15 ng/mL, clinical stage T1c-T2a and Gleason score 3 + 3 or 3 + 4 on needle biopsy), and underwent radical prostatectomy between 2000 and 2014. Extensive disease was defined as having Gleason pattern 4/5 in bilateral lobes, any extraprostatic extension, seminal vesicle invasion or lymph node invasion. Both lobes of the prostate were scored on magnetic resonance imaging. Preoperative characteristics including biopsy and magnetic resonance imaging data were used to predict extensive disease. Results: Among our cohort of 98 patients, 40% (95% CI 30–50%) had extensive disease. A total of 33% (95% CI 24–43%) had Gleason pattern 4/5 in both lobes with a median Gleason pattern 4/5 tumor volume in the biopsy negative lobe of 0.06 cm3, 17 patients had pathological tumor stage ≥3 and one patient had lymph node invasion. Conclusions: An important number of patients meeting the focal therapy consensus meeting inclusion criteria can present extensive disease. Further studies using targeted biopsies might provide more accurate information about the selection of focal therapy candidates.

AB - Objective: To examine a set of proposed eligibility factors for hemi-ablative focal therapy in prostate cancer and to determine the likelihood of residual extensive disease. Methods: We retrospectively analyzed data from 98 patients with unilateral prostate cancer on biopsy with detailed tumor maps from whole-mount slides and preoperative magnetic resonance imaging data. These patients met the focal therapy consensus meeting inclusion criteria (prostate-specific antigen <15 ng/mL, clinical stage T1c-T2a and Gleason score 3 + 3 or 3 + 4 on needle biopsy), and underwent radical prostatectomy between 2000 and 2014. Extensive disease was defined as having Gleason pattern 4/5 in bilateral lobes, any extraprostatic extension, seminal vesicle invasion or lymph node invasion. Both lobes of the prostate were scored on magnetic resonance imaging. Preoperative characteristics including biopsy and magnetic resonance imaging data were used to predict extensive disease. Results: Among our cohort of 98 patients, 40% (95% CI 30–50%) had extensive disease. A total of 33% (95% CI 24–43%) had Gleason pattern 4/5 in both lobes with a median Gleason pattern 4/5 tumor volume in the biopsy negative lobe of 0.06 cm3, 17 patients had pathological tumor stage ≥3 and one patient had lymph node invasion. Conclusions: An important number of patients meeting the focal therapy consensus meeting inclusion criteria can present extensive disease. Further studies using targeted biopsies might provide more accurate information about the selection of focal therapy candidates.

KW - ablation techniques

KW - biopsy

KW - magnetic resonance imaging

KW - pathology

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85076358123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076358123&partnerID=8YFLogxK

U2 - 10.1111/iju.14161

DO - 10.1111/iju.14161

M3 - Article

AN - SCOPUS:85076358123

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

ER -